




Curriculum Vitae

** CV must be written in English*

Personal Information	
Title (i.e. Pf., Dr., etc.)	Dr
Name (First Name/ Middle Name /Last Name)	Michael Chiorean
Degree (i.e. MD, MSc, PhD, etc.)	MD
Country	USA
Affiliation	Swedish Medical Center
E-mail	Michael.chiorean@swedish.org
	
Educational Background	
Univ. of Medicine and Pharm., Cluj-N., Romania – MD – Sept 1992 Residency, UMF Cluj-Napoca, Romania – Internal Medicine & Gastroenterology - Nov 1992 Research Fellowship, Univ. Perugia, Italy – Translational Gastroenterology - June 1995 Residency, Mayo Clinic, Rochester, MN – Internal Medicine – Sept 2000 Fellowship, Mayo Clinic, Rochester, MN – Gastroenterology – September 2003	
Professional Career	
2021-present Director, IBD center, Digestive Health Institute, Swedish Medical Center, Seattle, WA USA 2012-2021 Director, Inflammatory Bowel Disease Group, Virginia Mason 2017-present Clinical Associate Professor of Medicine, University of Washington, Seattle, WA 2011-2012 Associate Professor of Medicine, Indiana University School of Medicine, Indianapolis, IN 2004-2011 Assistant Professor of Medicine, Gastroenterology, Indiana University, Indianapolis, IN 2003-2004 Assistant Professor of Medicine, Gastroenterology, University of MN, Minneapolis, MN 2001-2003 Instructor of Medicine, Mayo Clinic, Rochester, MN	
Research field	
IBD outcomes research IBD clinical trials Interventional IBD Small bowel enteroscopy	
Main Scientific Publications	
<ol style="list-style-type: none"> Sandborn WJ, Vermeire S, Chiorean M, et al. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies. <i>Lancet</i>. 2023 Apr 8;401(10383):1159-1171. Danese S, Panaccione R, Abreu MT, Chiorean MV, et al. Efficacy and safety of approximately 3 years of continuous ozanimod in moderately to severely active ulcerative colitis: interim analysis of the True North open-label extension. <i>J Crohns Colitis</i>. 2024;18(2)264-274. Chiorean M, Ha C, Hur P, et al. Experience with Tofacitinib in Patients with Ulcerative Colitis: Data from a United States Claims Database. <i>Dig Dis Sci</i>. 2023 Oct;68(10):3985-3993. Chiorean M, Daperno M, Lees CW, et al. Modeling of Treatment Outcomes with Tofacitinib Maintenance Therapy in Patients with Ulcerative Colitis: A Post Hoc Analysis of Data from the OCTAVE Clinical Program. <i>Adv Ther</i>. 2023 Oct;40(10):4440-4459. 	



5. Sands BE, Schreiber S, Blumenstein I, **Chiorean MV**, et al. Clinician's Guide to Using Ozanimod for the Treatment of Ulcerative Colitis. *J Crohns Colitis*. 2023;17(12):2012-2025.
6. Allegretti JR, Gecse KB, **Chiorean MV**, et al. Early recapture of response with tofacitinib 10 mg twice daily in patients with ulcerative colitis in OCTAVE Open following dose reduction or treatment interruption in OCTAVE Sustain. *J Gastroenterol Hepatol*. 2024 Feb;39(2):264-271. doi: 10.1111/jgh.16386. Epub 2023 Nov 12. PMID: 37953548.
7. Desai M, Ausk K, Brannan D, **Chiorean M**, et al. Use of a Novel Artificial Intelligence System Leads to the Detection of Significantly Higher Number of Adenomas During Screening and Surveillance Colonoscopy: Results From a Large, Prospective, US Multicenter, Randomized Clinical Trial. *Am J Gastroenterol*. 2024 Feb 23. doi: 10.14309/ajg.0000000000002664. Epub ahead of print. PMID: 38235741.
8. Yarur AJ, **Chiorean MV**, Panés J, et al. Achievement of clinical, endoscopic, and histologic outcomes in patients with ulcerative colitis treated with etrasimod, and association with fecal calprotectin and C-reactive protein: results from the Phase 2 OASIS trial. *J Crohns Colitis*. 2024;18(6):885-894
9. Wei Q, Mease PJ, **Chiorean M**, et al. Machine learning to understand risks for severe COVID-19 outcomes: a retrospective cohort study of immune-mediated inflammatory diseases, immunomodulatory medications and comorbidities in a large US healthcare system. *Lancet Digit Health*. 2024;6(5):e309
10. **Chiorean M**, Jiang J, Candela N, et al. Real-world clinical outcomes and healthcare costs in patients with Crohn's disease treated with vedolizumab versus ustekinumab in the United States. *Curr Med Res Opin*. 2024;40(5):877-885